LONDON (Alliance News) - Hemodynamic monitoring company LiDCO PLC said on Thursday that its year-to-date sales are currently in line with the year before, due to the strong performance from its High Usage Programme.
Particularly in the US, recurring revenue have risen by 95% from the year before in local currency.
On Wednesday, two US customers signed multi-year contracts for the High Usage Programme.
As a result, LiDCO's trading has remained in line with management expectations.
Shares in LiDCO were up 1.3% at 7.34 pence on Thursday.
